Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...
Zydus Lifesciences Limited reported a 30 per cent year-on-year increase in net profit to ₹1,023.5 crore for the quarter ended December 31, 2024, driven by robust performance in its US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback